Immix Biopharma Investor Presentation Deck

Nexcella Resolves Neurotoxicity No Parkinson's Like Symptoms Broad Hospital Access (can access vast majority of hospitals in the US) Resolving CAR-T Neurotoxicity Short Hospital Stay (average-3 days) No Deaths Across 58 Patients in Clinical Trial ●●● IMMIX S BIOPHARMA 5

View entire presentation